Content deleted Content added
Line 18:
== Clinical significance ==
{{split section|CD20 antagonist|date=November 2015}}
CD20 is the target of the [[monoclonal antibodies]] (mAb) [[rituximab]], [[obinutuzumab]], [[Ibritumomab tiuxetan]], and [[tositumomab]], which are all active agents in the treatment of all B cell [[lymphoma]]s and [[leukemias]]. It has been shown that inhibition of BCR signalling by ibrutinib affects the expression of CD20 and the efficacy of anti-CD20 antibodies. <ref>{{cite journal|pmid=27480113}}</ref>
The anti-CD20 mAB [[Ofatumumab]] ([[Genmab]]) was approved by FDA in Oct 2009 for [[Chronic lymphocytic leukemia]].
| |||